<p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - 获取免费报告) 的股票在周六的交易中达到了新的 52 周高点。该公司的股价最高达到 6.47 美元，最后交易价格为 5.30 美元，交易量为 30793967 股。该股票之前的收盘价为 2.95 美元。</p>
<h2>NovaBay Pharmaceuticals 股票上涨 79.7%</h2>
<p>该股票的 50 日移动平均线为 1.46 美元，200 日移动平均线为 1.25 美元。</p>
<h2>NovaBay Pharmaceuticals 宣布分红</h2>
<p>该公司最近还宣布了一项分红，已于 9 月 29 日（星期一）支付。10 月 1 日（星期三）的股东记录获得每股 0.80 美元的分红。这代表了 3,791.0% 的收益率。该分红的除息日期为 9 月 30 日（星期二）。</p>
<h2>NovaBay Pharmaceuticals 的机构交易</h2>
<p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Ground Swell Capital LLC 在第三季度购买了价值 25,000 美元的 NovaBay Pharmaceuticals 新股份。Apollon Wealth Management LLC 在第三季度获得了价值 35,000 美元的 NovaBay Pharmaceuticals 新头寸。最后，C2C Wealth Management LLC 在第二季度将其在 NovaBay Pharmaceuticals 的持股增加了 78.2%。C2C Wealth Management LLC 现在拥有 98,000 股该生物制药公司的股票，价值 57,000 美元，此前在上个季度又购买了 43,000 股。对冲基金和其他机构投资者持有该公司 23.25% 的股份。</p>
<h2>NovaBay Pharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>NovaBay Pharmaceuticals, Inc 是一家临床阶段的生物技术公司，专注于开发和商业化新型非抗生素抗感染产品，旨在调节先天免疫反应。利用其专有的 Aganocide®技术，该公司的合成抗微生物化合物能够靶向并中和病原体，而不会导致抗生素耐药性。NovaBay 的研发工作集中在眼科、皮肤科和伤口护理应用上，旨在解决感染控制和炎症管理中的未满足需求。</p>
<p>该公司的主要商业产品包括 Avenova®，一种用于管理慢性睑板腺功能障碍和睑缘炎的眼睑和睫毛清洁溶液，以及 NeutroPhase®，一种用于急性和慢性伤口灌洗的纯次氯酸伤口和皮肤清洁剂。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 NovaBay Pharmaceuticals</li>
<li>如何投资生物技术股票</li>
<li>这三家银行在年末前上涨，但这种趋势会持续吗？</li>
<li>什么是盈利惊喜？</li>
<li>三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>什么是澳大利亚证券交易所（ASX）</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 NovaBay Pharmaceuticals 吗？</h2>
<p>在你考虑 NovaBay Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 NovaBay Pharmaceuticals 并不在名单上。</p>
<p>虽然 NovaBay Pharmaceuticals 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NovaBay制药

<p>NovaBay 制药（NYSEAMERICAN:NBY）股票创下 52 周新高，交易价格最高达到 6.47 美元，最终收于 5.30 美元，较前一交易日的 2.95 美元上涨了 79.7%。该股票的交易量达到 30,793,967 股。公司最近宣布每股派息 0.80 美元，收益率高达 3,791.0%。机构投资者已调整其持仓，对冲基金持有该股票的 23.25%。NovaBay 专注于非抗生素抗感染产品，利用 Aganocide®技术进行感染控制</p>

<p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - Get Free Report) shares reached a new 52-week high during trading on Saturday . The company traded as high as $6.47 and last traded at $5.30, with a volume of 30793967 shares trading hands. The stock had previously closed at $2.95.</p>
<div class="lb-trans"><p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - 获取免费报告) 的股票在周六的交易中达到了新的 52 周高点。该公司的股价最高达到 6.47 美元，最后交易价格为 5.30 美元，交易量为 30793967 股。该股票之前的收盘价为 2.95 美元。</p>
</div><h2>NovaBay Pharmaceuticals Trading Up 79.7%</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 股票上涨 79.7%</h2>
</div><p>The stock has a fifty day moving average of $1.46 and a 200-day moving average of $1.25.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均线为 1.46 美元，200 日移动平均线为 1.25 美元。</p>
</div><h2>NovaBay Pharmaceuticals Announces Dividend</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 宣布分红</h2>
</div><p>The business also recently announced a dividend, which was paid on Monday, September 29th. Shareholders of record on Wednesday, October 1st were given a dividend of $0.80 per share. This represents a yield of 3,791.0%. The ex-dividend date of this dividend was Tuesday, September 30th.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项分红，已于 9 月 29 日（星期一）支付。10 月 1 日（星期三）的股东记录获得每股 0.80 美元的分红。这代表了 3,791.0% 的收益率。该分红的除息日期为 9 月 30 日（星期二）。</p>
</div><h2>Institutional Trading of NovaBay Pharmaceuticals</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. Ground Swell Capital LLC purchased a new stake in shares of NovaBay Pharmaceuticals in the 3rd quarter valued at $25,000. Apollon Wealth Management LLC acquired a new position in NovaBay Pharmaceuticals during the third quarter valued at $35,000. Finally, C2C Wealth Management LLC boosted its holdings in NovaBay Pharmaceuticals by 78.2% in the second quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 43,000 shares during the last quarter. Hedge funds and other institutional investors own 23.25% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Ground Swell Capital LLC 在第三季度购买了价值 25,000 美元的 NovaBay Pharmaceuticals 新股份。Apollon Wealth Management LLC 在第三季度获得了价值 35,000 美元的 NovaBay Pharmaceuticals 新头寸。最后，C2C Wealth Management LLC 在第二季度将其在 NovaBay Pharmaceuticals 的持股增加了 78.2%。C2C Wealth Management LLC 现在拥有 98,000 股该生物制药公司的股票，价值 57,000 美元，此前在上个季度又购买了 43,000 股。对冲基金和其他机构投资者持有该公司 23.25% 的股份。</p>
</div><h2>NovaBay Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company's synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay's research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.</p>
<div class="lb-trans"><p>NovaBay Pharmaceuticals, Inc 是一家临床阶段的生物技术公司，专注于开发和商业化新型非抗生素抗感染产品，旨在调节先天免疫反应。利用其专有的 Aganocide®技术，该公司的合成抗微生物化合物能够靶向并中和病原体，而不会导致抗生素耐药性。NovaBay 的研发工作集中在眼科、皮肤科和伤口护理应用上，旨在解决感染控制和炎症管理中的未满足需求。</p>
</div><p>The company's primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.</p>
<div class="lb-trans"><p>该公司的主要商业产品包括 Avenova®，一种用于管理慢性睑板腺功能障碍和睑缘炎的眼睑和睫毛清洁溶液，以及 NeutroPhase®，一种用于急性和慢性伤口灌洗的纯次氯酸伤口和皮肤清洁剂。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than NovaBay Pharmaceuticals</li>
<li>How to Invest in Biotech Stocks</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>What is an Earnings Surprise?</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 NovaBay Pharmaceuticals</li>
<li>如何投资生物技术股票</li>
<li>这三家银行在年末前上涨，但这种趋势会持续吗？</li>
<li>什么是盈利惊喜？</li>
<li>三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>什么是澳大利亚证券交易所（ASX）</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in NovaBay Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 NovaBay Pharmaceuticals 吗？</h2>
</div><p>Before you consider NovaBay Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 NovaBay Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovaBay Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 NovaBay Pharmaceuticals 并不在名单上。</p>
</div><p>While NovaBay Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 NovaBay Pharmaceuticals 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

NovaBay 制药（NYSEAMERICAN:NBY）创下 12 个月新高 - 现在是买入的好时机吗？